Clovis Oncology Prevails in European Patent Proceedings Related to Rubraca

Clovis Oncology Prevails in European Patent Proceedings Related to Rubraca

Source: 
CP Wire
snippet: 
  • Ruling will confirm European regulatory exclusivity for Rubraca until at least 2028
  • Clovis also recently received a patent for using Rubraca in high doses to treat cancer in the US